RELATING TO TERMINAL ILLNESSES.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 8 Sponsors

Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 12/31/2050. (SD1)

Chamber: Senate
Introduced: Jan 8, 2025
Last action: Jan 8, 2025 — Pending Introduction.
Session: 2026
Momentum: 58 · Moderate

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base Passed First Chamber — base rate 11%, measured from HI's completed sessions
Momentum +2 58/100 from the pace of recorded action
Time since last action -22 640 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.